Home › Funds › Redmile Group, LLC › ALXO
Redmile Group, LLC position in ALXO
ALX ONCOLOGY HLDGS INC · Health Care
Redmile Group, LLC reported holding 7,392,504 shares of ALXO (ALX ONCOLOGY HLDGS INC) in its Q2 2026 13F filing — a position valued at US$15.3M, representing 1.03% of its reported portfolio and ranking #21 among its reported holdings. Redmile Group, LLC has disclosed ALXO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Redmile Group, LLC's ALXO position evolved
Redmile Group, LLC first disclosed a stake in ALXO in Q3 2023 at 1,283,289 shares (US$6.2M). The position peaked in Q4 2023 at 3,659,264 shares, worth US$54.5M. Across 12 filings, Redmile Group, LLC increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 7,392,504 shares valued at US$15.3M — a reduction of -571,684 shares quarter over quarter.. Notable position changes include a 185% increase in Q4 2023 (shares fell 25% over the following quarter), a 144% increase in Q1 2026 (shares rose 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.28M | $6.16M | New |
| Q4 2023 | 3.66M | $54.49M | Add |
| Q1 2024 | 4.33M | $48.24M | Add |
| Q2 2024 | 4.04M | $24.34M | Reduce |
| Q3 2024 | 3.84M | $6.98M | Reduce |
| Q4 2024 | 3.69M | $6.16M | Reduce |
| Q1 2025 | 3.64M | $2.27M | Reduce |
| Q2 2025 | 3.39M | $1.41M | Reduce |
| Q3 2025 | 3.33M | $6.10M | Reduce |
| Q4 2025 | 3.26M | $3.69M | Reduce |
| Q1 2026 | 7.96M | $15.97M | Add |
| Q2 2026 | 7.39M | $15.30M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALXO and 13F data
ALXO (ALX ONCOLOGY HLDGS INC) is a Health Care company. 35 other funds we track also report a position in ALXO — the largest reported positions include venBio Partners LLC (US$26.7M), SILVERARC CAPITAL MANAGEMENT, LLC (US$11.9M), TCG Crossover Management, LLC (US$11.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALXO
- venBio Partners LLC 12.88M sh · $26.67M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 5.74M sh · $11.89M · Q2 2026
- TCG Crossover Management, LLC 5.66M sh · $11.71M · Q2 2026
- Vivo Capital, LLC 3.18M sh · $6.59M · Q2 2026
- 5AM Venture Management, LLC 3.06M sh · $6.33M · Q2 2026
- Almitas Capital LLC 2.94M sh · $6.08M · Q2 2026
More on Redmile Group, LLC
FAQ
How long has Redmile Group, LLC held ALXO?
Redmile Group, LLC has disclosed ALXO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Redmile Group, LLC's current position in ALXO?
As of Q2 2026, Redmile Group, LLC holds 7.39M shares of ALXO (ALX ONCOLOGY HLDGS INC), valued at $15.30M, representing 1.03% of its reported portfolio and ranking #21.
Has Redmile Group, LLC been buying or selling ALXO?
In the latest 13F filing (Q2 2026), Redmile Group, LLC reduced its position in ALXO. The position peaked in Q4 2023 at 3.66M shares.
Which other funds hold ALXO?
Other major institutional holders of ALXO include venBio Partners LLC, SILVERARC CAPITAL MANAGEMENT, LLC, TCG Crossover Management, LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.